STUDresearch · Peptide
Eloralintide
Also known as
LY3841136 · Elo / Elora (forum shorthand) · Lilly selective amylin · SARA (selective amylin receptor agonist talk)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Subcutaneous (weekly)
Metabolic / GLP-1 class
Systemic once-weekly selective amylin receptor agonist.
What people say
Eloralintide (LY3841136) is Lilly’s investigational long-acting selective amylin receptor agonist. It is a once-weekly subcutaneous trial drug, not an approved GLP-1 medicine or a short-acting pramlintide product.
Doses people talk about
The rows retain fixed and escalation trial arms, informal increments and the combination-study amounts while preserving their different evidence boundaries.
How it may feel
Two inspected accounts point in different directions. A heavily stacked gray-product user reported delayed nausea waves after a 1 mg injection. A blinded eloralintide/macupatide trial participant reported early abdominal discomfort, fatigue and constipation but no nausea or vomiting, followed by lower appetite through week 3; assignment was unknown.
Phase 2 weekly trial arms1, 3, 6 and 9 mg fixed arms; 6–9 and 3–9 mg escalation schemes
These arms ran over 48 weeks in an obesity trial.
Community increment discussion1.5, 3, 6 and 9 mg weekly steps
This is a preserved research-forum sequence, not a validated titration schedule.
Gray-product reports1 mg first-injection reports and a later 6 mg eloralintide-only report
Product identity and fill were not independently verified.
Combination-trial amountsEloralintide 3 or 9 mg with tirzepatide 5 or 15 mg
These are investigational combination-study arms, not a do-it-yourself stack chart.
Half-life & effect duration
- Half-life in the body
- Injected · study estimateAbout 14 days
- Reported study rangeAbout 13.9–15.8 days
- Felt duration people report
- Stacked-use accountMild headache and delayed waves of nausea after an injection
- Blinded combination-trial accountDay-1 abdominal discomfort; early fatigue and constipation; lower appetite through week 3
Cycles people discuss
Phase 2 studied once-weekly treatment for 48 weeks. Eloralintide has no approved maintenance course, and a trial escalation or discontinuation schedule is not a community cycle.
Timing
Human Phase 1 work describes a half-life of about 14 days; the reported 13.9–15.8-day conference range was not directly rechecked. Neither establishes how long appetite, nausea, fatigue or constipation will be felt.
Stacks
Phase 2 studied eloralintide alone. Lilly has also studied it with tirzepatide, while one blinded community diary involved a possible eloralintide/macupatide assignment. These settings do not establish a home combination protocol.
Watch for
Nausea / bloating: Trial and gray logs. Selling point is “less than a max GLP,” not “none.”
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The Phase 1 paper describes eloralintide’s half-life as approximately 14 days.
The reviewed Phase 1 paper studied weekly subcutaneous eloralintide in adults with overweight or obesity and describes a roughly two-week half-life. Its cited ADA 882-P conference abstract is indexed with a mean range of 13.9–15.8 days; direct abstract access returned 403, so that precise range is retained as attributed reporting, not independently rechecked here.
The numeric value reflects the paper’s approximate 14-day statement, not fresh verification of the precise conference range. Early-phase PK does not establish an approved dose, community-product identity or subjective-effect duration.
- Bhattachar et al. — Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept (opens in a new tab)Introduction and Discussion §4: roughly 2 weeks/~14-day half-life, citing ADA abstract 882-P (reference 12). The current 12-week multiple-dose study used weekly subcutaneous administration in adults with overweight or obesity.Wiley full text was actually reviewed and supports the approximate 14-day statement. The 13.9–15.8-day mean range is indexed to Bhattachar et al., ADA 882-P, DOI 10.2337/db25-882-P; direct access to the ADA publisher page returned 403, so the precise abstract was not content-reviewed here. Small sponsor study; no approved use or measured subjective duration.
Felt duration people report
The inspected reports do not establish one isolated eloralintide felt-duration window.
A highly stacked gray-product account described mild headache and delayed nausea waves after a Saturday 1 mg injection. A blinded combo-trial participant described day-1 abdominal discomfort, early fatigue and constipation, no nausea or vomiting, and lower appetite through week 3, but allocation was unknown.
One product was unverified and used alongside many agents; the other report was blinded among placebo, macupatide, eloralintide and combination arms. Neither isolates eloralintide clearance or causality.
- Reddit r/Eloralintide — Started on Saturday 1 mg, waves of nausea today (opens in a new tab)Original post and replies describe a Saturday 1 mg injection, mild headache and Tuesday nausea waves while listing retatrutide and multiple hormone or peptide co-agents.Unverified product, extensive simultaneous-agent confounding and no controlled assessment; the account cannot isolate eloralintide.
- Reddit r/GLP1ResearchTalk — Week 1 update, Eli Lilly eloralintide/macupatide trial (opens in a new tab)Original post and same-author week-3 replies describe day-1 abdominal discomfort, early fatigue and constipation, no nausea or vomiting, and sustained appetite reduction while assignment remained blinded.The author could have received placebo, macupatide, eloralintide or their combination; self-report cannot identify the active agent or quantify pharmacokinetics.
Other context in this card
- Billings et al. — Eloralintide once weekly in adults with obesity or overweight (opens in a new tab)48-week randomized Phase 2 trial with fixed 1, 3, 6 and 9 mg weekly arms plus 6–9 mg and 3–9 mg escalation arms; safety follow-up extended 10 weeks because of the long half-life.Investigational obesity trial and secondary-hosted article PDF; it does not establish community-product identity or a use recommendation.
What people say
- r/Zepbound read: “20-ish percent at max ≈ CagriSema talk, but nausea ~25% like SURMOUNT 5 mg.” That is how the rooms framed it. forum
- Appetite: Gray-vial logs: decreased appetite, some bloating, not a stimulant. forum
- Lean-mass hope: Amylin class is sold as “more satiety, maybe kinder to muscle than max GLP.” Human composition for elo specifically is still thin next to the scale %. forum
- Phase 2 weight (48 wk, no T2D): Mean loss about −9% (1 mg) to −20% (9 mg and 6–9 mg) vs −0.4% placebo. 9 mg ~−21.3 kg in the high arm writeups. trial
- + tirzepatide (Phase 1b, 2026 abstract talk): Combo headlines like ~20% at 16 weeks (tirz 5 + elo 9) and high-20s at 32 weeks (tirz 15 + elo 9) — small, fast-titration, dropouts. Forums called it “bariatric-looking” and also “they titrated too fast.” trial
Doses people talk about
- Research-talk increments: r/GLP1ResearchTalk: 1.5 → 3 → 6 → 9 mg. forum
- Gray start logs: 1 mg weekly shows up as a first pin. 6 mg “Elo only” is a later log. anecdote
- Do not paste pramlintide mealtime mcg onto this. Weekly mg. forum
- Combo trial: Elo 3 or 9 mg next to tirz 5 or 15 in the 2026 abstract people screenshotted. Not a DIY stack chart. trial
- Framing: Trial mg and gray-vial copies — not a label. Identity on a marketplace vial is the first risk. forum
- Phase 2 weekly arms: 1, 3, 6, 9 mg, plus 6–9 and 3–9 escalation schemes, 48 weeks. trial
How it may feel
- Honest density: Most “how it feels” is trial GI tables plus a small r/Eloralintide / research-talk logbook. Not tadalafil-level n. forum
- Week 1 gray logs: One account described “terrible nausea the first week… down 12 lb… decreased appetite.” Another highly stacked account took 1 mg Saturday and described mild headache followed by waves of nausea on Tuesday; identity and attribution were unverified. anecdote
- Blinded combo-trial account: One eloralintide/macupatide Phase 2b participant described day-1 abdominal discomfort, early fatigue and constipation but no nausea or vomiting; the same author reported markedly lower appetite through week 3. Assignment remained unknown. anecdote
- Maintenance: Trial nausea mostly mild–moderate; selling point vs GLP is “less vomit.” Gray users still report waves. forum
- If nothing: Amylin is slower than a 15 mg tirz honeymoon in some research-talk posts. forum
- Titration weeks (trial): GI clustered on the way up. Slower steps were the Phase 2 lesson vs faster Phase 1b combo dropouts. trial
Cycles people discuss
- Titrate or drop out: Fast combo titration = the dropout story. forum
- Weekly trial courses: Phase 2 studied 48 weeks of treatment followed by 10 weeks of safety follow-up. Not an open-ended course or a 6-week blast. trial
- No approved maintenance. Phase 3 is the 2026–27 calendar. trial
Timing
- Human PK and reported range: The Phase 1 paper describes an approximately 14-day half-life with once-weekly SC study dosing. The ADA 882-P abstract is indexed with a 13.9–15.8-day mean range, but its full content could not be directly rechecked (403). The original r/Zepbound ~14-day figure remains attributed community talk, not a label or a felt-duration estimate. trialforum
- Missed week: No dense “I skipped and crashed” lore yet. forum
- Phase 1: Dose-proportional weekly exposure; GI were not the main AE list in the small 12-week POC (appetite down, headache, fatigue). trial
- Why weekly: Amylin analogs in this generation are depot-ish vs pramlintide’s mealtime pins. trial
More on what it is
- Why people talk about it: r/Zepbound pasted the Lancet Phase 2: up to ~20% at 48 weeks on 9 mg with nausea rates they compared to SURMOUNT 5 mg. Peptide suppliers got “time to synthesize Elo” threads the same week. forum
- Peptaura / gray: Catalog SKUs exist. r/Eloralintide and r/GLP1ResearchTalk already have n=1 pin logs. Those are not Lilly pens. forum
- Not the same as: Pramlintide (short, mealtime). Cagrilintide / CagriSema. Petrelintide (Zealand/Roche amylin). Retatrutide. forum
- What it is: Lilly’s long-acting selective amylin agonist (LY3841136). Once-weekly shot in trials. Not approved as of the 2026 Phase 2/3 wave. trial
- How it works (plain): Amylin is the partner hormone that comes out with insulin. This analog says “you’re full” and slows the stomach without being another GLP-1. trial
- Evidence: Phase 2 in *The Lancet* (263 people, 48 weeks). Phase 1 weekly-well-tolerated writeup. Phase 1b + tirzepatide abstracts in 2026. Phase 3 ENLIGHTEN talk started. trial
Stacks
- + macupatide in a research-talk diary. Thin. anecdote
- Vs CagriSema, not with it by default. Two amylin stories. forum
- Solo in Phase 2. trial
- + tirzepatide in Lilly combo work — the 2026 hype stack, not a settled home protocol. trial
Storage notes
- No STUD unit chart. Marketplace vials are not Lilly pens. forum
- Fridge talk follows other research peptides in those Discords. forum
Watch for
- Nausea / bloating: Trial and gray logs. Selling point is “less than a max GLP,” not “none.” forum
- Not FDA-approved. Trial product ≠ Peptaura SKU. forum
- Amylin + GLP stacking is a clinical experiment, not a Wolverine stack. forum
- Identity: “Elo” on a vial may be wishful labeling. forum
- Gallbladder / under-fuel: Class obesity-drug cautions still apply if the scale moves fast. forum
- Vomit / dropout when stacked and rushed. Phase 1b combo lesson. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.